GILEAD SCIENCES, INC.
FOSTER CITY, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 6, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.46B2026 Q3
Positions5
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%
What Changed This Quarter?
No notable portfolio changes this quarter.Top Holdings
RCUS
Arcus Biosciences
55.5%
LKFT
Lakefront Biotherapeutics
34.2%
ASMB
Assembly Biosciences
8.0%
KYTX
Kyverna Therapeutics
1.9%
Xilio Therape…
Xilio Therapeutics
0.4%
New / Increased
0 new · 0 increased
Reduced / Exited
0 reduced · 0 sold out
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.